arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

KIORA PHARMACEUTICALS INC

KPRX
$2.63 ▲ +0.13 (+5.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

KIORA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -18.0%
FCF / Share $-0.76
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.42M
↓ -10.3%
Operating Margin Operating profit as % of sales
82.6%
↑ +167.9%
FCF / Share Free cash flow per share
$-0.76
↓ -18.3%
Long-Term Debt Long-term obligations
$278.19K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters